Following on from information provided to NICE by the company in June 2017 the appraisal of NGR-TNF for previously treated advanced malignant pleural mesothelioma [ID655] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 655

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
21 December 2022 Discontinued. Following on from information provided to NICE by the company in June 2017 the appraisal of NGR-TNF for previously treated advanced malignant pleural mesothelioma [ID655] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
05 July 2017 Suspended. The company have advised that they will not be pursuing a licensing application for NGR-TNF from the European Medicines Authority for this indication at this time.
05 July 2017 The Department of Health has asked NICE to conduct a Single Technology Appraisal of NGR-TNF for previously treated advanced malignant pleural Mesothelioma. However, the company have advised that they will not be pursuing a licensing application for NGR-TNF from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes
21 April 2017 Referral
21 April 2017 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual